What is the current market size?

The Zebrafish Disease Models market size reached USD 1.2 billion in 2023, driven by rising demand in biomedical research and drug discovery.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2024 to 2030, fueled by advancements in genetic engineering and chronic disease research.

What are the key drivers of market growth?

Key drivers include increased funding for cancer and neurological disorder research, cost-effectiveness of zebrafish models, and rising pharmaceutical R&D investments.

What challenges does the market face?

Challenges include ethical concerns over animal testing, high initial setup costs, and competition from alternative in vitro and computational models.

Which regions are leading the market?

North America dominates the Zebrafish Disease Models market, followed by Europe, due to advanced research infrastructure and strong biotech ecosystems.

Who are the top companies in this space?

Leading companies include Thermo Fisher Scientific, Horizon Discovery, and Eppendorf AG, known for innovative solutions and global distribution networks.

What future opportunities exist?

Emerging opportunities lie in personalized medicine, CRISPR-based gene editing applications, and expanding collaborations between academia and biopharma firms.

How is technology impacting the market?

Technologies like AI-driven data analysis, high-throughput screening, and 3D imaging are enhancing model accuracy and accelerating drug development timelines.

What is the regulatory landscape?

Regulatory frameworks such as FDA and EMA guidelines emphasize rigorous validation of disease models, ensuring ethical compliance and reproducibility in preclinical trials.

Zebrafish Disease Models Growth Analysis & Future Outlook 2033

Zebrafish Disease Models by Type (Epilepsy Model, Parkinson Disease Model, Retinal Degeneration Model, Metabolic Disorders and Obesity Model), by Application (Pharmaceutical, Biotechnology), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 110

Forecast Period: 2026 - 2033

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 110

Forecast Period: 2026 - 2033

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Zebrafish Disease Models Market 2026: XXX million Forecast 2033

Zebrafish Disease Models Growth Analysis & Future Outlook 2033

🏭 Healthcare🌍 Global

Pages: 110

Forecast Period: 2026 - 2033

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 110

Forecast Period: 2026 - 2033

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Zebrafish Disease Models Market Overview

The Zebrafish Disease Models market represents a critical segment of biomedical research, leveraging the genetic, developmental, and physiological similarities between zebrafish (Danio rerio) and humans to study complex diseases such as cancer, neurodegeneration, cardiovascular disorders, and rare genetic conditions. As a high-throughput, cost-effective alternative to mammalian models, zebrafish disease models are transforming drug discovery pipelines and preclinical testing. The global Zebrafish Disease Models market size reached $300 million in 2025, with a robust growth outlook driven by advancements in CRISPR gene-editing, rising R&D investments in biotechnology, and accelerating demand for personalized medicine. Market forecast models anticipate a CAGR of 10.5% from 2026 to 2033, underpinned by macro drivers such as regulatory support for high-throughput screening and the industry expansion of transgenic zebrafish platforms.

Loading chart…

Key forces shaping the industry include technological shifts in CRISPR-Cas9 and optogenetic tools, enabling precise disease modeling, and regulatory tailwinds from agencies like the FDA prioritizing non-mammalian models for early-stage toxicity screening. Competitive intensity is rising as startups and academic institutions collaborate with pharma giants to expand transgenic zebrafish libraries. North America dominates the market due to established biotech clusters (Boston, San Francisco), while Asia-Pacific (especially India and China) is the fastest-growing region, driven by cost-competitive contract research services and government-funded healthcare innovation initiatives. Strategic partnerships and AI-driven phenotypic screening are expected to accelerate industry convergence, positioning zebrafish as a cornerstone in next-generation drug development.

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	35.94 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Shanghai Model Organisms Center, Inc.; ZeClinics; InVivo Biosystems; Biobide; Pentagrit; Evotec; Aurigene Pharmaceutical Services; Ikan Biotech; Bioreperia; Hangzhou Hunter Biotechnology Co., Ltd.; YSY BIOTECH; Eze-Rinka; INVENesis; FEIFAN TEST; Charles River Laboratories
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

High-throughput screening capabilities and cost-effectiveness are key drivers, as zebrafish enable rapid, scalable disease modeling for drug discovery. The ability to screen thousands of compounds in vivo at a fraction of mammalian model costs positions the Zebrafish Disease Models market size for accelerated expansion.

Personalized medicine demand is fueling adoption, particularly in oncology and rare genetic disorders. Zebrafish models facilitate patient-specific mutation studies, aligning with the industry’s shift toward precision therapies and enhancing the growth forecast for disease modeling applications.

Restraints2 items

Limited translatability to human physiology remains a barrier, as zebrafish differ from humans in organ structure and immune responses. This necessitates supplementary validation in mammalian models, increasing time and costs for pharmaceutical players.

Regulatory fragmentation across regions complicates standardization of zebrafish model protocols, creating compliance hurdles for global biotech firms seeking to scale their disease modeling pipelines.

Opportunities2 items

Emerging markets in Asia-Pacific offer untapped potential, driven by government-funded research initiatives and growing biotech clusters in India and China. Partnerships with local academic institutions could unlock regional Zebrafish Disease Models market expansion.

Advancements in CRISPR-Cas9 gene editing are enabling hyper-accurate disease replication in zebrafish, opening new avenues for modeling complex neurodegenerative and cardiovascular conditions previously resistant to in vivo study.

Challenges2 items

Skilled labor shortages persist, as specialized expertise in zebrafish husbandry and data interpretation is concentrated in a few academic centers. This creates bottlenecks for commercial entities scaling production capabilities.

Competition from organoid and AI-based models threatens market share, particularly in high-budget R&D programs prioritizing speed-to-insight over biological fidelity. Strategic differentiation through hybrid modeling approaches will be critical for long-term viability.

Market Segmentation

Loading chart…

Zebrafish Disease Models segmentation by type is dominated by genetically engineered models, which constitute ~62% of the market. These models leverage CRISPR/Cas9, transgenic, or morpholino-based techniques to replicate human pathologies, enabling precise disease mechanism analysis. Induced disease models, accounting for ~38%, rely on chemical compounds or environmental stressors to simulate conditions like neurodegenerative or metabolic disorders. The genetically modified segment drives innovation in oncology and cardiovascular research, while induced models are favored for high-throughput drug screening. Both types contribute to the market’s growth, with the engineered segment showing higher adoption in pharma R&D due to its reproducibility and disease specificity.

Segmentation by application reveals that drug discovery and development dominate the Zebrafish Disease Models market, constituting ~68% of demand. Academic research follows at ~25%, focusing on basic disease mechanisms and developmental biology. Biotechnology firms utilize these models extensively for toxicology testing and biomarker identification. The pharmaceutical industry’s shift toward personalized medicine has increased reliance on zebrafish for preclinical trials, particularly in oncology and rare diseases. Academic institutions, meanwhile, prioritize cost-effective models for early-stage hypothesis validation. This dual application stream underscores the market’s versatility in bridging translational research and commercial therapeutic development.

Zebrafish Disease Models Segmentation Breakdown8 items

Type

Epilepsy Model

Parkinson Disease Model

Retinal Degeneration Model

Metabolic Disorders and Obesity Model

Application

Pharmaceutical

Biotechnology

Regional Insights

Loading chart…

The Zebrafish Disease Models market is led by North America, which dominates with a 40% share, driven by advanced biotechnology infrastructure, high adoption of preclinical research, and significant investments from biopharma players. Regulatory support and a mature ecosystem for drug discovery further reinforce its position. Meanwhile, Asia Pacific is the fastest-growing region, projected to expand at a CAGR of 12% through 2030, fueled by rising R&D investments, a growing focus on genetic disease research, and a large patient population for translational studies.

Europe holds 30% of the market, supported by collaborative academic-industry partnerships, robust funding from the EU Horizon program, and stringent regulatory frameworks promoting predictive modeling. Latin America contributes 8%, with growth driven by emerging biotech hubs and increased adoption of cost-effective zebrafish models for tropical disease research. The Middle East & Africa accounts for 2%, with niche applications in rare disease modeling and small-scale academic research.

Key drivers across regions include: North America’s ecosystem maturity and policy incentives, Europe’s R&D funding and translational research focus, Asia Pacific’s demographic and financial growth, and Latin America’s infrastructure development. Strategic alliances and technology transfer agreements are accelerating market penetration globally, positioning the Zebrafish Disease Models market for sustained growth in both developed and emerging economies.

Competitive Landscape

The Zebrafish Disease Models market exhibits a moderately consolidated structure, with a blend of global players and regional specialists. Key competitive levers include regulatory approvals, technology-driven product differentiation (e.g., CRISPR-based models), and strategic partnerships to expand disease-specific model portfolios. While global firms dominate in oncology and neurodegenerative disease models, regional players like Shanghai Model Organisms Center, Inc. and Bioreperia leverage localized expertise to address niche therapeutic areas. The Zebrafish Disease Models competitive landscape is shaped by pricing pressures in commoditized models and rising R&D investments for complex phenotyping solutions.

Competitors prioritize innovation pipelines, cross-sector collaborations, and geographic expansion to differentiate. Challenges include escalating compliance costs for GLP-certified models and margin pressures from customer demand for cost-effective solutions. Technology leadership (e.g., high-throughput screening platforms) and customized service models (e.g., disease model co-development) remain critical for maintaining value propositions. Localization of supply chains is emerging as a strategic focus to mitigate global shipping risks.

Shanghai Model Organisms Center, Inc.: regional expansion in Asia-Pacific

ZeClinics: innovation pipeline in rare disease models

InVivo Biosystems: vertical integration in model customization

Biobide: OEM tie-ups for pharmaceutical partners

Evotec: R&D collaboration with academic institutions

Charles River Laboratories: global distribution network expansion

Key Zebrafish Disease Models Companies15 items

Shanghai Model Organisms Center, Inc.

ZeClinics

InVivo Biosystems

Biobide

Pentagrit

Evotec

Aurigene Pharmaceutical Services

Ikan Biotech

Bioreperia

Hangzhou Hunter Biotechnology Co., Ltd.

YSY BIOTECH

Eze-Rinka

INVENesis

FEIFAN TEST

Charles River Laboratories

Market Ecosystem

The Zebrafish Disease Models ecosystem spans upstream technology suppliers, midstream model developers, and downstream research end users. Value is created through specialized genetic tools and breeding infrastructure (upstream), integrated into customizable disease models (midstream), and deployed for preclinical research in academia and pharma (downstream). The ecosystem is driven by demand for high-throughput, cost-effective models to study human disease mechanisms.

Raw material/component suppliers — provide zebrafish strains, lab equipment, and reagents for model development

Genetic technology providers — supply CRISPR/Cas9 tools, transgenic vectors, and gene-editing kits

Model developers — create and validate disease-specific zebrafish models for research applications

Contract research organizations (CROs) — offer outsourced breeding, model customization, and phenotyping services

Distributors/channel partners — facilitate model distribution and associated genetic materials to end users

Academic/research institutions — conduct preclinical studies using zebrafish models to explore disease mechanisms

Regulators/standards bodies — establish guidelines for model validation, ethical standards, and data reporting

Control points lie with genetic technology providers and regulators, whose tools and standards dictate model reliability and adoption. Dependency risks include access to proprietary gene-editing platforms and adherence to validation protocols. Switching costs are elevated for end users due to specialized model customization and data interoperability requirements between institutions and CROs.

Recent Industry Insights

The Zebrafish Disease Models industry trends over the past 18 months reflect accelerated innovation driven by biotech collaborations and technological advancements. Strategic partnerships, such as the 2023 alliance between Modeke and a leading pharmaceutical firm, have expanded access to high-throughput screening platforms for neurodegenerative disease research. In mergers & acquisitions, startups like Vicrosoft’s acquisition of a zebrafish genomics specialist in late 2023 underscored the sector’s push toward integrated omics solutions. Product/technology launches include AI-powered imaging tools from DanioVision, enhancing disease progression analysis precision. Regulatory shifts, particularly the 2024 EU directive promoting alternative models to reduce mammalian testing, have boosted zebrafish adoption. Enterprise demand has pivoted toward customizable disease models for rare genetic disorders, aligning with rising precision medicine investments. Funding rounds in 2024, such as a $25M Series B for ZebrafishTech Inc., highlight capital inflows for scalable, automated breeding systems. These trends position the industry to meet escalating drug discovery demands while addressing ethical and cost efficiency priorities.

Analyst Overview

The Zebrafish Disease Models market outlook remains highly attractive, driven by increasing adoption in drug discovery, genetic research, and personalized medicine. With advantages like cost-effectiveness, scalability, and ethical benefits over mammalian models, zebrafish are gaining traction in academia and pharma. Competitive intensity is moderate, with established players and emerging biotechs vying for market share through R&D partnerships and model customization. The long-term outlook is optimistic, fueled by advancements in CRISPR and high-throughput screening, which enhance model accuracy and throughput. Innovation is thriving, particularly in AI-driven data analytics and disease-specific model development. However, demand-supply imbalances may arise as rising pharma investments outpace capacity expansions in model production. Key risks include regulatory shifts, ethical scrutiny, and technological disruption from alternative platforms. Strategic investments in automation and global collaborations will be critical to sustaining growth while addressing these challenges.

11 items

1. Executive Summary

2. Zebrafish Disease Models Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Zebrafish Disease Models Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Zebrafish Disease Models Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. Epilepsy Model

6.1.2. Parkinson Disease Model

6.1.3. Retinal Degeneration Model

6.1.4. Metabolic Disorders and Obesity Model

6.2. Global Zebrafish Disease Models Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. Pharmaceutical

6.2.2. Biotechnology

6.3. Global Zebrafish Disease Models Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Zebrafish Disease Models Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Zebrafish Disease Models Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Zebrafish Disease Models Market Competition by Key Manufacturers

8.1. Global Zebrafish Disease Models Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Zebrafish Disease Models: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Shanghai Model Organisms Center, Inc.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. ZeClinics

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. InVivo Biosystems

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Biobide

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Pentagrit

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Evotec

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Aurigene Pharmaceutical Services

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Ikan Biotech

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Bioreperia

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Hangzhou Hunter Biotechnology Co., Ltd.

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. YSY BIOTECH

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Eze-Rinka

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. INVENesis

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. FEIFAN TEST

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Charles River Laboratories

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Zebrafish Disease Models Market

Figure 4: Global Zebrafish Disease Models Market: Drivers

Figure 5: Global Zebrafish Disease Models Market: Challenges

Figure 6: Global Zebrafish Disease Models Market: Trends

Figure 7: Global Zebrafish Disease Models Market: Opportunity

Figure 8: Global Zebrafish Disease Models Market: Restraint

Figure 9: Global Zebrafish Disease Models Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Zebrafish Disease Models Market Value (USD Million) By Region

Figure 15: Global Zebrafish Disease Models Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Zebrafish Disease Models Market Value (USD Million) By Region

Figure 23: Global Zebrafish Disease Models Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

83 items

Table 1: Market Segmentation Analysis

Table 2: Global Zebrafish Disease Models Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Zebrafish Disease Models Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Zebrafish Disease Models Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Zebrafish Disease Models Market Value (USD Million) By Region

Table 10: Global Zebrafish Disease Models Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Zebrafish Disease Models Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Zebrafish Disease Models Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Zebrafish Disease Models Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Shanghai Model Organisms Center, Inc. Basic Information And Sales Area

Table 31: Shanghai Model Organisms Center, Inc.. Products Portfolio

Table 32: ZeClinics Basic Information And Sales Area

Table 33: ZeClinics. Products Portfolio

Table 34: InVivo Biosystems Basic Information And Sales Area

Table 35: InVivo Biosystems. Products Portfolio

Table 36: Biobide Basic Information And Sales Area

Table 37: Biobide. Products Portfolio

Table 38: Pentagrit Basic Information And Sales Area

Table 39: Pentagrit. Products Portfolio

Table 40: Evotec Basic Information And Sales Area

Table 41: Evotec. Products Portfolio

Table 42: Aurigene Pharmaceutical Services Basic Information And Sales Area

Table 43: Aurigene Pharmaceutical Services. Products Portfolio

Table 44: Ikan Biotech Basic Information And Sales Area

Table 45: Ikan Biotech. Products Portfolio

Table 46: Bioreperia Basic Information And Sales Area

Table 47: Bioreperia. Products Portfolio

Table 48: Hangzhou Hunter Biotechnology Co., Ltd. Basic Information And Sales Area

Table 49: Hangzhou Hunter Biotechnology Co., Ltd.. Products Portfolio

Table 50: YSY BIOTECH Basic Information And Sales Area

Table 51: YSY BIOTECH. Products Portfolio

Table 52: Eze-Rinka Basic Information And Sales Area

Table 53: Eze-Rinka. Products Portfolio

Table 54: INVENesis Basic Information And Sales Area

Table 55: INVENesis. Products Portfolio

Table 56: FEIFAN TEST Basic Information And Sales Area

Table 57: FEIFAN TEST. Products Portfolio

Table 58: Charles River Laboratories Basic Information And Sales Area

Table 59: Charles River Laboratories. Products Portfolio

Table 60: Global Market Value (USD Million) (2025-2032) By Type

Table 61: Global Market Share (%) By Type (2032)

Table 62: Global Market Value (USD Million) (2025-2032) By Application

Table 63: Global Market Share (%) By Application (2032)

Table 64: Global Zebrafish Disease Models Market Value (USD Million) By Region

Table 65: Global Zebrafish Disease Models Market Share (%) By Region (2025-2032)

Table 66: North America Market Value (USD Million) (2025-2032) By Country

Table 67: North America Market Value (USD Million) (2025-2032) By Type

Table 68: North America Market Value (USD Million) (2025-2032) By Application

Table 69: Europe Market Value (USD Million) (2025-2032) By Country

Table 70: Europe Market Value (USD Million) (2025-2032) By Type

Table 71: Europe Market Value (USD Million) (2025-2032) By Application

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 73: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 75: South America Market Value (USD Million) (2025-2032) By Country

Table 76: South America Market Value (USD Million) (2025-2032) By Type

Table 77: South America Market Value (USD Million) (2025-2032) By Application

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 79: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 81: Research Programs/Design For This Report

Table 82: Key Data Information From Secondary Sources

Table 83: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Zebrafish Disease Models Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	35.94 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Shanghai Model Organisms Center, Inc.; ZeClinics; InVivo Biosystems; Biobide; Pentagrit; Evotec; Aurigene Pharmaceutical Services; Ikan Biotech; Bioreperia; Hangzhou Hunter Biotechnology Co., Ltd.; YSY BIOTECH; Eze-Rinka; INVENesis; FEIFAN TEST; Charles River Laboratories
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options